Tolerability studies of candidate ad drugs and efficacy of poly(L-lysine succinylated)-hydroxychloroquine (PLS-HCQ) in a transgenic ad mouse model
Ended Purchase Order Awarded Last action
- Contract number
- 75N95022P00542
- Awardee
-
Scantox Neuro GMBH UEI ED41XCPBEPU1
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $249,000
Award facts
- Opportunity
-
- SOURCES SOUGHT: Tolerability studies of candidate AD drugs and efficacy of Poly(L-lysine succinylated)-hydroxychloroquine (PLS-HCQ) in a transgenic AD mouse model Pre-Solicitation · 75N95022Q00316 · Posted Jun 21, 2022
- Contract value 100% obligated
- $249,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute on Aging National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Austria
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Vendor DUNS or Name Change - Non-Novation | $0 | |
| Original award | $249,000 |
About this award
The National Institute on Aging awarded a $249,000 firm fixed-price purchase order to Scantox Neuro GMBH, an Austria-based pharmaceutical research firm specializing in neurological and Alzheimer's disease studies. The contract, awarded on September 30, 2022, with an ultimate completion date of May 2, 2025, supports tolerability studies of candidate Alzheimer's disease drugs and efficacy testing of poly(L-lysine succinylated)-hydroxychloroquine (PLS-HCQ) in a transgenic Alzheimer's mouse model. This work aligns with the NIA's broader drug repurposing initiatives, including the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and PREVENT-AD studies, which seek to identify and validate potential new treatment options through experimental validation of compounds. No small business set-aside was designated for this award.
This purchase order represents one component of a larger Indefinite Delivery Contract valued at $2.326 million between the NIA and Scantox Neuro GMBH extending through May 31, 2025. The contract was subsequently subject to a Notice of Termination for Convenience issued in March 2025 as part of the FY26 UDO Initiative implementing the President's Department of Government Efficiency cost efficiency program. Scantox Neuro GMBH has received multiple federal contract awards from the NIA totaling approximately $1.37 million, establishing the firm as a key service provider for advanced scientific research involving experimental drug validation and pharmacological assessment using transgenic mouse models for Alzheimer's disease research.
Quick answers
Who was awarded contract 75N95022P00542?
75N95022P00542 was awarded to Scantox Neuro GMBH by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2022.
How much is contract 75N95022P00542 worth?
The government has obligated $249,000 on 75N95022P00542.
Which agency awarded contract 75N95022P00542?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022P00542, with funding from National Institute on Aging (National Institutes of Health).
Was contract 75N95022P00542 competed?
The extent of competition for 75N95022P00542 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award